XENE
Xenon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$39.19
+2.51%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$39.41
From 52W high−44.77%
Volume1.63M
Market cap$3.80B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$39.41
From 52W high
−44.77%
Volume
1.63M
Market cap
$3.80B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.9x
P/E (TTM)
—
RSI (14)
51.3
MomentumView details →
1D Return
+2.51%
YTD Return
−13.39%
SummaryUpdated Jun 1, 2026
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Burnaby, Canada. The company specializes in developing neurological therapeutics by targeting ion channels, particularly potassium and sodium channels in the brain. Xenon has built its expertise around understanding the genetic basis of neurological disorders and translating these insights into targeted drug therapies. The company went public in 2014 and has since advanced multiple drug candidates through clinical trials, with its lead program <b>azetukalner</b> (XEN1101) currently in Phase 3 trials for epilepsy and depression.
Similar companies
Latest newsMore news →
Xenon Pharmaceuticals Inc. announced that it will report its third-quarter 2026 financial results and provide a business update after U.S. markets close on November 9, 2026.2d agoXenon Pharmaceuticals announced that Phase 2 proof-of-concept studies of XEN1701 and XEN1120 in acute pain are expected to begin in the first half of 2027.7d agoXenon Pharmaceuticals announced preclinical data in cynomolgus monkeys showing significant reductions in capsaicin-evoked heat pain for NaV1.7 and KV7 compounds.7d ago